The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The GINA 2025 asthma update includes new guidance on T2 biomarkers, asthma in young children, and climate change, as well as many updated charts and tools.

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare ...

Luminal amoebicides (such as paromomycin, diloxanide furoate and iodoquinol) act on organisms in the intestinal lumen, but are ineffective against organisms in tissue.

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the disease, including Trelegy (fluticasone furoate, umeclidinium, and ...

Rationale Estimating the causal effect of an intervention at individual level, also called individual treatment effect (ITE), may help in identifying response prior to the intervention. Objectives We ...